These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice? Soria F; D'Andrea D; Pohar K; Shariat SF; Lotan Y Curr Opin Urol; 2018 Nov; 28(6):577-583. PubMed ID: 30157039 [TBL] [Abstract][Full Text] [Related]
29. Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging. Shkolyar E; Zhao Q; Mach KE; Teslovich NC; Lee TJ; Cox S; Skinner EC; Lu Y; Liao JC Urol Oncol; 2021 Aug; 39(8):497.e9-497.e15. PubMed ID: 33766467 [TBL] [Abstract][Full Text] [Related]
30. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12]. Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124 [TBL] [Abstract][Full Text] [Related]
31. Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles. Oeyen E; Hoekx L; De Wachter S; Baldewijns M; Ameye F; Mertens I Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769831 [TBL] [Abstract][Full Text] [Related]
32. Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer. Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Aufderklamm S; Böttge J; Rausch S; Mischinger J; Bier S; Gakis G; Kuehs U; Stenzl A; Schwentner C Dis Markers; 2014; 2014():973406. PubMed ID: 25587206 [TBL] [Abstract][Full Text] [Related]
33. Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer. Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Donat SM; Bochner BH; Dalbagni G J Urol; 2013 Oct; 190(4):1187-91. PubMed ID: 23680310 [TBL] [Abstract][Full Text] [Related]
34. Current approaches for identifying high-risk non-muscle invasive bladder cancer. Sanli O; Lotan Y Expert Rev Anticancer Ther; 2018 Mar; 18(3):223-235. PubMed ID: 29359984 [TBL] [Abstract][Full Text] [Related]
35. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438 [TBL] [Abstract][Full Text] [Related]
36. [Imaging and pathology of bladder tumors]. Roy C; Merran S J Radiol; 2002 Jun; 83(6 Pt 2):843-59, discussion 861-2. PubMed ID: 12218858 [TBL] [Abstract][Full Text] [Related]
37. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359 [TBL] [Abstract][Full Text] [Related]
38. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. Mbeutcha A; Lucca I; Mathieu R; Lotan Y; Shariat SF Urol Clin North Am; 2016 Feb; 43(1):47-62. PubMed ID: 26614028 [TBL] [Abstract][Full Text] [Related]
39. Follow-up in non-muscle invasive bladder cancer: facts and future. Witjes JA World J Urol; 2021 Nov; 39(11):4047-4053. PubMed ID: 33367941 [TBL] [Abstract][Full Text] [Related]
40. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer. Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]